Encuesta de calidad de vida II- La sociedad de Canadá de LMC presenta resultados muy preliminares de nuestra encuesta de calidad de vida II en la Escuela Europea reciente de Conferencia de Hematología (ESH). El cartel fue titulado “Estudio de calidad de vida II, el viaje de LMC y manejo de enfermedades a través de...Read More
For several years, the CML Society of Canada has been engaging with the federal government of Canada and the members of the Pharmaceutical Manufacturing Price Review Board (PMPRB), regarding the much needed updates to the PMPRB guidelines (1) as well as the need for Canada’s Universal Healthcare to include pharmaceuticals. In fact, the Liberal party...Read More
It is a cytogenetic technique that is used to detect/localize DNA sequneces on chromosomes. Flourescent in-situ Hybridization (FISH) is a big word, to understand it better, let’s break it down. Flourescent – flourescent probes. The flourescent probes are made from fragments of DNA that were isolated, purified, and amplified for use in the Human Genome...Read More
GLEEVEC® is indicated for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase. GLEEVEC® is also indicated for the treatment of adult patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase or in chronic phase (after failure of interferon-alpha therapy). GLEEVEC® is also...Read More
Raising Awareness was our Key Motivator! There are about 5,100 Canadians living with CML. Every day someone in Canada is diagnosed with CML Although we have made significant improvements, once a week someone living with CML in Canada will die. No known cause or prevention of CML Some patients in Canada still struggle to access and/or pay...Read More
We are excited to announce that there is another new option that will soon be available for Canadian CML patients in Canada. Pending Pan Canadian Oncology Drug Review and INESS Approval. ARIAD ANNOUNCES APPROVAL OF ICLUSIG (AS PONATINIB HYDROCHLORIDE) IN CANADA Cambridge, MA, April 6, 2015 –- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), today announced that...Read More
ICLUSIG ™ ICLUSIG ™ (Ponatinib) is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom other tyrosine kinase inhibitor (TKI) therapy is not appropriate, including CML or Ph+ALL that is T315I mutation positive or...Read More
Import Expert Panel advice for CML Patients: Advice for people with chronic myeloid leukemia on COVID-19The iCMLf is sharing an expert statement specifically for chronic phase CML patients on the novel coronavirus and the COVID-19 disease. The novel Coronavirus and the COVID-19 DiseaseInformation for Chronic Phase Chronic Myeloid Leukemia PatientsState of the Art as of...Read More
Notice regarding independent patient activities linked to the generic imatinib mesylate issue: The CML Society of Canada does not endorse or condone independent patient activity that is aimed at inciting other patients, friends and family members to SPAM government offices with email alleging that generic imatinib mesylate is harmful to patients. In fact there is...Read More
